Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Third consecutive week of biotech IPOs
- A biotech company focused on immune-mediated diseases extended the biotech initial public offering resurgence, raising $289 million in an upsized Nasdaq offering (17 million shares at $17/share). The deal marks the third consecutive week of biotech IPOs, highlighting renewed investor appetite for the sector, particularly clinical-stage immunology and inflammation (I&I) companies.
- According to Endpoints News, the proceeds will fund the company’s pipeline of three I&I drug candidates and its multispecific antibody platform, which is designed to create biologics that bind multiple targets for potentially stronger and longer-lasting efficacy. The company expects its lead candidate to enter Phase 2 in the first half of 2027 with two additional programs advancing into Phase 1 around the same time.
Major medical device manufacturer agrees to take-private deal
- A global investment firm has agreed to acquire a medical device manufacturer in an all-cash transaction valued at approximately $5.7 billion, offering shareholders about $127 per share, a 51% premium to the stock price before a strategic review was announced in April. The deal is expected to close by year-end, subject to shareholder and regulatory approvals.
- The medical device manufacturer believes going private will provide greater flexibility and long-term capital to expand its contract development and manufacturing business, including investments in capacity, technology and innovation, according to Medtech Dive.
MHRA sets out guidance on ‘AI scribes’
- Last week the Medicines and Healthcare products Regulatory Agency, working with National Health Services (NHS) England, published guidance clarifying how existing medical device regulations apply to ambient voice technology (AVT) products used in health and care settings.
- The guidance confirms that AVT products intended to support diagnosis, treatment or prevention, or those that take automated actions without clinician review, fall within medical device regulation and must meet relevant safety and performance requirements. The move is intended to provide greater certainty for NHS organizations and suppliers adopting artificial intelligence-enabled documentation tools.
Major CRO partners to bring AI into clinical trial design and execution
- A major clinical research organization (CRO) has entered a multi-year partnership to integrate AI across its clinical trial operations, enhancing site selection, study feasibility, protocol design, enrollment forecasting and risk detection through the CRO’s platforms. The goal is to improve trial efficiency and address operational bottlenecks such as patient enrollment delays.
- According to Fierce Biotech, the collaboration reflects growing adoption of AI in biopharma and clinical development, with sponsors gaining access to the CRO’s trial intelligence through AI-powered tools.
Lab monkey shortage highlights China’s rapid rise in biotech innovation
- China’s booming biotech sector is driving a sharp shortage of laboratory monkeys used in preclinical drug testing, causing prices to surge to as much as $26,000 per monkey, nearly double a year ago. The shortage is fueled by strong demand for biologics, antibody-drug conjugates, bispecifics and other next-generation therapies that require primate safety studies before entering clinical trials, reports Bloomberg.
- The supply crunch risks slowing China’s rapid drug development engine, with some studies facing delays of four to 10 months as companies compete for limited primate capacity.
For more insights in life sciences, check out RSM’s industry outlook.
